Dimenhydrinate and Apixaban drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dimenhydrinate (dimenhydrinate) and Apixaban (apixaban). Common drug interactions include haemorrhagic transformation stroke among females and general physical health deterioration among males.

The phase IV clinical study analyzes what interactions people have when they take Dimenhydrinate and Apixaban. It is created by eHealthMe based on reports of 68 people who take the same drugs from the FDA, and is updated regularly.

What is Dimenhydrinate?

Dimenhydrinate has active ingredients of dimenhydrinate. It is often used in nausea. eHealthMe is studying from 6,644 Dimenhydrinate users. Check the latest studies of Dimenhydrinate.

What is Apixaban?

Apixaban has active ingredients of apixaban. It is often used in blood clots. eHealthMe is studying from 60,351 Apixaban users. Check the latest studies of Apixaban.



On Jul, 14, 2026

68 people who take Dimenhydrinate and Apixaban together, and have interactions are studied.

Dimenhydrinate and Apixaban drug interactions.

What are the common drug interactions of Dimenhydrinate and Apixaban, by gender? *:

female:

  1. Haemorrhagic transformation stroke (haemorrhages develop inside areas of ischemia)
  2. Headache (pain in head)
  3. Increased appetite
  4. Influenza like illness
  5. Injury
  6. Insomnia (sleeplessness)
  7. Intermittent claudication
  8. Intestinal ischaemia (decreased supply of oxygenated blood to the intestines)
  9. Joint swelling
  10. Lethargy (tiredness)

male:

  1. General physical health deterioration (weak health status)
  2. Haematochezia (passage of stools containing blood)
  3. Constipation
  4. Cough
  5. Decreased appetite
  6. Dizziness
  7. Headache (pain in head)
  8. Hypertension (high blood pressure)
  9. Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
  10. Pneumonia

What are the common drug interactions of Dimenhydrinate and Apixaban, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Arthralgia (joint pain)
  2. Blood creatinine increased
  3. Blood urine present
  4. Butterfly rash
  5. C-reactive protein increased
  6. Drug ineffective
  7. Haemoglobin decreased
  8. Lupus nephritis (a chronic inflammatory autoimmune disorder that may affect kidney tissue)
  9. Mouth ulceration (mouth ulcers)
  10. Nephropathy (damage to or disease of a kidney)

30-39:

  1. Oropharyngeal pain
  2. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  3. Pruritus (severe itching of the skin)
  4. Pyrexia (fever)
  5. Rash pruritic (redness with itching)
  6. Weight decreased
  7. Abortion spontaneous (naturally occurring miscarriage)
  8. Alopecia (absence of hair from areas of the body)
  9. Blood pressure increased
  10. Chest pain

40-49:

n/a

50-59:

  1. Drug dependence
  2. Rebound effect (take-back effect)

60+:

  1. Fall
  2. General physical health deterioration (weak health status)
  3. Haematemesis (vomiting of blood)
  4. Respiration (transport of oxygen from the outside air to the cells within tissues)
  5. Plasma cell myeloma (cancer that begins in plasma cells)
  6. Renal failure (kidney dysfunction)
  7. Decreased appetite
  8. Abdominal discomfort
  9. Chest pain
  10. Cough

What are the existing conditions these people have? *

  1. Stress And Anxiety: 7 people, 10.29%
  2. Pain: 7 people, 10.29%
  3. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 6 people, 8.82%
  4. Urinary Tract Infection: 4 people, 5.88%
  5. Takayasu's Arteritis (an inflammation of the aorta -- the artery that carries blood from the heart to the rest of the body): 4 people, 5.88%
  6. Headache (pain in head): 4 people, 5.88%
  7. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Dimenhydrinate and Apixaban?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Dimenhydrinate and Apixaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Dimenhydrinate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Apixaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dimenhydrinate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Apixaban and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on dimenhydrinate and apixaban (the active ingredients of Dimenhydrinate and Apixaban, respectively), and Dimenhydrinate and Apixaban (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: